journal article·2016-08-17Open access

Application of Box–Behnken design to prepare gentamicin-loaded calcium carbonate nanoparticles

Solmaz Maleki Dizaj, Farzaneh Lotfipour, Mohammad Barzegar-Jalali, Mohammad-Hossein Zarrintan, Khosro Adibkia

Abstract

The aim of this research was to prepare and optimize calcium carbonate (CaCO3) nanoparticles as carriers for gentamicin sulfate. A chemical precipitation method was used to prepare the gentamicin sulfate-loaded CaCO3 nanoparticles. A 3-factor, 3-level Box-Behnken design was used for the optimization procedure, with the molar ratio of CaCl2: Na2CO3 (X1), the concentration of drug (X2), and the speed of homogenization (X3) as the independent variables. The particle size and entrapment efficiency were considered as response variables. Mathematical equations and response surface plots were used, along with the counter plots, to relate the dependent and independent variables. The results indicated that the speed of homogenization was the main variable contributing to particle size and entrapment efficiency. The combined effect of all three independent variables was also evaluated. Using the response optimization design, the optimized Xl-X3 levels were predicted. An optimized formulation was then prepared according to these levels, resulting in a particle size of 80.23 nm and an entrapment efficiency of 30.80%. It was concluded that the chemical precipitation technique, together with the Box-Behnken experimental design methodology, could be successfully used to optimize the formulation of drug-incorporated calcium carbonate nanoparticles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Science, Tabriz, Iran

Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

References (39)

Show source-provided references
1. Abdelghany SM · Int J Nanomed · 2012 · 7 · 4053
2. Acton QA. 2012. Immunosuppressive Agents: Advances in Research and Application ,Atlanta, Georgia: ScholarlyBrief, Scholarly Editions.
3. Adibkia K · African J Pharm Pharmacol · 2012 · 6 · 941
4. 10.1080/1061186070145312510.1080/10611860701453125 ↗
5. 10.3168/jds.S0022-0302(96)76454-810.3168/jds.S0022-0302(96)76454-8 ↗
6. 10.1086/31513810.1086/315138 ↗
7. 10.2147/nano.2006.1.2.11710.2147/nano.2006.1.2.117 ↗
8. Chaudhary S · Artif Cells Nanomed Biotechnol · 2015 · 1
9. 10.1039/c1mb05147d10.1039/c1mb05147d ↗
10. 10.1002/jbm.a.3079510.1002/jbm.a.30795 ↗
11. Daraee H · Artif Cells Nanomed Biotechnol. · 2014 · 1
12. 10.1016/S0731-7085(99)00192-210.1016/S0731-7085(99)00192-2 ↗
13. 10.1002/jbm.82025080610.1002/jbm.820250806 ↗
14. 10.1007/s40005-013-0098-810.1007/s40005-013-0098-8 ↗
15. 10.1016/S0168-3659(98)00121-710.1016/S0168-3659(98)00121-7 ↗
16. Hallan SS · Artif Cells Nanomed Biotechnol · 2014 · 1
17. 10.1089/15209150376381640910.1089/152091503763816409 ↗
18. 10.1155/2012/53401010.1155/2012/534010 ↗
19. 10.1016/j.carbpol.2011.03.05110.1016/j.carbpol.2011.03.051 ↗
20. 10.1016/j.nano.2010.06.00310.1016/j.nano.2010.06.003 ↗
21. 10.18433/J3TP4T10.18433/J3TP4T ↗
22. 10.1080/0265204080236518210.1080/02652040802365182 ↗
23. 10.1016/0168-3659(95)00123-910.1016/0168-3659(95)00123-9 ↗
24. 10.1016/j.lwt.2010.07.01210.1016/j.lwt.2010.07.012 ↗
25. 10.1016/j.colsurfb.2011.05.05010.1016/j.colsurfb.2011.05.050 ↗
26. 10.2334/josnusd.51.6910.2334/josnusd.51.69 ↗
27. Noori Koopaei M · Iran J Pharm Res · 2014 · 13 · 819
28. 10.1002/jbm.82026070510.1002/jbm.820260705 ↗
29. 10.1155/2013/37093810.1155/2013/370938 ↗
30. 10.1007/s00604-010-0523-x10.1007/s00604-010-0523-x ↗
31. 10.1016/j.injury.2006.04.01710.1016/j.injury.2006.04.017 ↗
32. 10.1039/c0sm00316f10.1039/c0sm00316f ↗
33. 10.1111/j.1365-2273.1995.tb00026.x10.1111/j.1365-2273.1995.tb00026.x ↗
34. 10.1111/j.1745-4549.1982.tb00650.x10.1111/j.1745-4549.1982.tb00650.x ↗
35. 10.1016/j.jconrel.2004.11.01510.1016/j.jconrel.2004.11.015 ↗
36. 10.1016/j.ijpharm.2005.11.00410.1016/j.ijpharm.2005.11.004 ↗
37. 10.1128/IAI.66.11.5238-5243.199810.1128/IAI.66.11.5238-5243.1998 ↗
38. 10.1080/026520402100005842910.1080/0265204021000058429 ↗
39. 10.1093/emboj/17.22.643710.1093/emboj/17.22.6437 ↗